These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 17631934)
21. Anti-HIV effect of iron chelators: different mechanisms involved. van Asbeck BS; Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ J Clin Virol; 2001 Feb; 20(3):141-7. PubMed ID: 11166663 [TBL] [Abstract][Full Text] [Related]
22. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770 [TBL] [Abstract][Full Text] [Related]
23. Objectives and mechanism of iron chelation therapy. Hershko C; Link G; Konijn AM; Cabantchik ZI Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658 [TBL] [Abstract][Full Text] [Related]
24. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Liang SX; Richardson DR Carcinogenesis; 2003 Oct; 24(10):1601-14. PubMed ID: 12869419 [TBL] [Abstract][Full Text] [Related]
25. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173 [TBL] [Abstract][Full Text] [Related]
26. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes. Salerno D; Hasham MG; Marshall R; Garriga J; Tsygankov AY; Graña X Gene; 2007 Dec; 405(1-2):65-78. PubMed ID: 17949927 [TBL] [Abstract][Full Text] [Related]
27. The new orally active iron chelator ICL670A exhibits a higher antiproliferative effect in human hepatocyte cultures than O-trensox. Chantrel-Groussard K; Gaboriau F; Pasdeloup N; Havouis R; Nick H; Pierre JL; Brissot P; Lescoat G Eur J Pharmacol; 2006 Jul; 541(3):129-37. PubMed ID: 16765341 [TBL] [Abstract][Full Text] [Related]
28. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Glickstein H; El RB; Shvartsman M; Cabantchik ZI Blood; 2005 Nov; 106(9):3242-50. PubMed ID: 16020512 [TBL] [Abstract][Full Text] [Related]
29. Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. Zhou M; Deng L; Lacoste V; Park HU; Pumfery A; Kashanchi F; Brady JN; Kumar A J Virol; 2004 Dec; 78(24):13522-33. PubMed ID: 15564463 [TBL] [Abstract][Full Text] [Related]
30. Effect of transcription peptide inhibitors on HIV-1 replication. Van Duyne R; Cardenas J; Easley R; Wu W; Kehn-Hall K; Klase Z; Mendez S; Zeng C; Chen H; Saifuddin M; Kashanchi F Virology; 2008 Jul; 376(2):308-22. PubMed ID: 18455747 [TBL] [Abstract][Full Text] [Related]
31. Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. Sappey C; Boelaert JR; Legrand-Poels S; Forceille C; Favier A; Piette J AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1049-61. PubMed ID: 8554902 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. Georgiou NA; van der Bruggen T; Oudshoorn M; Nottet HS; Marx JJ; van Asbeck BS J Infect Dis; 2000 Feb; 181(2):484-90. PubMed ID: 10669330 [TBL] [Abstract][Full Text] [Related]
33. Regulatory functions of Cdk9 and of cyclin T1 in HIV tat transactivation pathway gene expression. Romano G; Kasten M; De Falco G; Micheli P; Khalili K; Giordano A J Cell Biochem; 1999 Dec; 75(3):357-68. PubMed ID: 10536359 [TBL] [Abstract][Full Text] [Related]
34. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Lim CK; Kalinowski DS; Richardson DR Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550 [TBL] [Abstract][Full Text] [Related]
35. The effect of iron overload on in vitro HIV-1 infection. Traoré HN; Meyer D J Clin Virol; 2004 Dec; 31 Suppl 1():S92-8. PubMed ID: 15567100 [TBL] [Abstract][Full Text] [Related]
36. Iron chelation decreases human immunodeficiency virus-1 Tat potentiated tumor necrosis factor-induced NF-kappa B activation in Jurkat cells. Shatrov VA; Boelaert JR; Chouaib S; Dröge W; Lehmann V Eur Cytokine Netw; 1997 Mar; 8(1):37-43. PubMed ID: 9110146 [TBL] [Abstract][Full Text] [Related]
37. The role of Tat in HIV-1 replication: an activator and/or a suppressor? Liang C; Wainberg MA AIDS Rev; 2002; 4(1):41-9. PubMed ID: 11998784 [TBL] [Abstract][Full Text] [Related]